Latest On TransMedics Group, Inc (TMDX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-21 08:04 EST | News | TransMedics: Expensive, But High Potential | N/A |  |
| 2023-05-09 18:53 EST | News | TransMedics upsizes and prices $400M senior convertible notes | N/A | |
| 2023-05-09 04:48 EST | News | TransMedics prices and upsizes $400M senior convertible notes | N/A | |
| 2023-05-08 15:59 EST | News | TransMedics slips on plans to offer $300M convertible notes | N/A | |
| 2023-05-02 02:37 EST | News | TransMedics Group reports Q1 results, raises FY 2023 revenue guidance | N/A | |
About TransMedics Group, Inc (TMDX):
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor read more... heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
General
- Name TransMedics Group, Inc
- Symbol TMDX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Devices
- Full Time Employees 110
- Fiscal Year EndDecember
- IPO Date2019-05-02
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Web URLhttp://www.transmedics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 32.35
- Price/Book (Most Recent Quarter) 8.78
- Enterprise Value Revenue 32.02
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.07
- Next Year EPS Estimate -$0.60
- Next Quarter EPS Estimate -$0.17
- Profit Margin -112%
- Operating Margin -103%
- Return on Assets -13%
- Return on Equity -36%
- Revenue 25.64 million
- Earnings Per Share -$4.76
- Revenue Per Share $1.04
- Gross Profit 16.64 million
- Quarterly Earnings Growth 25.9%
Highlights
- Market Capitalization 1.22 billion
- EBITDA -23001000
- PE Ratio 1868.79
- Analyst Target Price $51.25
- Book Value Per Share $3.82
Share Statistics
- Shares Outstanding 27.37 million
- Shares Float 26.26 million
- % Held by Insiders 1186%
- % Held by Institutions 78.32%
- Shares Short 1.15 million
- Shares Short Prior Month 859251
- Short Ratio 1.11
- Short % of Float 6%
- Short % of Shares Outstanding 4%
Technicals
- 52 Week High $47.34
- 52 Week Low $11.15
- 50 Day Moving Average 32.15
- 200 Day Moving Average 20.07
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
TransMedics Group, Inc (TMDX) Dividend Calendar:
TransMedics Group, Inc (TMDX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
TransMedics Group, Inc (TMDX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
TransMedics Group, Inc (TMDX) Chart:
TransMedics Group, Inc (TMDX) News:
Below you will find a list of latest news for TransMedics Group, Inc (TMDX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
TransMedics Group, Inc (TMDX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest TMDX Trades:
TransMedics Group, Inc (TMDX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-04 | 8-K (Current report) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 8-K (Current report) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 8-K (Current report) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 8-K (Current report) | |
| 2020-05-28 | 8-K (Current report) | |
| 2020-05-27 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-05-26 | 8-K (Current report) | |
| 2020-05-26 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
TransMedics Group, Inc (TMDX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of TransMedics Group, Inc (TMDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1186%
Institutional Ownership: 7832%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-01 | John F Carey | VP of Operations | Sell | 2,000.00 | 17.59 | 35,180.00 | 3,200.00 | |
| 2020-09-01 | John F Carey | VP of Operations | Buy | 2,000.00 | 0.39 | 780.00 | 5,200.00 | |
| 2020-08-03 | John F Carey | VP of Operations | Sell | 142.00 | 18.96 | 2,692.32 | 3,200.00 | |
| 2020-08-03 | John F Carey | VP of Operations | Sell | 1,858.00 | 18.58 | 34,521.64 | 3,342.00 | |
| 2020-08-03 | John F Carey | VP of Operations | Buy | 2,000.00 | 2.21 | 4,420.00 | 5,200.00 | |
| 2020-07-01 | John F Carey | VP of Operations | Sell | 600.00 | 17.92 | 10,752.00 | 3,200.00 | |
| 2020-07-01 | John F Carey | VP of Operations | Sell | 1,400.00 | 16.73 | 23,422.00 | 3,800.00 | |
| 2020-07-01 | John F Carey | VP of Operations | Buy | 894.00 | 0.39 | 348.66 | 4,094.00 | |
| 2020-07-01 | John F Carey | VP of Operations | Buy | 1,106.00 | 2.21 | 2,444.26 | 5,200.00 | |
| 2020-06-01 | John F Carey | VP of Operations | Sell | 2,000.00 | 13.21 | 26,420.00 | 3,200.00 | |
| 2020-06-01 | John F Carey | VP of Operations | Buy | 2,000.00 | 0.39 | 780.00 | 5,200.00 | |
| 2020-05-01 | John F Carey | VP of Operations | Sell | 500.00 | 17.63 | 8,815.00 | 3,200.00 | |
| 2020-05-01 | John F Carey | VP of Operations | Sell | 1,500.00 | 16.86 | 25,290.00 | 3,700.00 | |
| 2020-05-01 | John F Carey | VP of Operations | Buy | 2,000.00 | 0.39 | 780.00 | 5,200.00 | |
| 2020-04-27 | Stephen Gordon | Chief Financial Officer | Sell | 9,900.00 | 18.00 | 178,200.00 | 18,571.00 | |
| 2020-04-22 | Stephen Gordon | Chief Financial Officer | Sell | 100.00 | 18.00 | 1,800.00 | 28,471.00 | |
| 2020-04-07 | John F Carey | VP of Operations | Sell | 2,000.00 | 13.10 | 26,200.00 | 3,200.00 | |
| 2020-04-07 | John F Carey | VP of Operations | Buy | 2,000.00 | 0.39 | 780.00 | 5,200.00 | |
| 2020-03-27 | Waleed H Hassanein | President & CEO | Buy | 100,000.00 | 0.39 | 39,000.00 | 215,429.00 | |
| 2020-03-02 | John F Carey | VP of Operations | Sell | 100.00 | 15.98 | 1,598.00 | 3,200.00 | |